Pirfenidone Promising for RA-Linked Interstitial Lung Disease
Phase 2 trial terminated early, underpowered to meet primary end point, but limited results suggest pirfenidone may slow progression of RA-ILD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.